We're currently a leading institution in Arizona and the surrounding states of New Mexico and Nevada approved to offer unique cellular therapies like Chimeric Antigen Receptor T-cell (CAR-T) for relapsed or refractory Acute Lymphoblastic Leukemia to patients 0-25 years old.